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Abstract 
Subclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo), defined as elevated 
thyroid-stimulating hormone (TSH) by normal free thyroxine (FT4), and subclinical hyperthyroidism 
(SHyper) with decreased or undetectable TSH and normal FT4. Up to 10% of the elderly have SHypo, 
which is usually asymptomatic. Individual participant data (IPD) analyses of prospective cohort studies 
from the international Thyroid Studies Collaboration show that SHypo is associated with increased 
coronary heart disease (CHD) mortality (Hazard Ratio [HR] 1,58 for TSH≥10 mIU/l, 95%CI 1.10-2.27), 
as well as increased risk of stroke, and heart failure (HF) for both higher and lower TSH. Small studies 
found that SHypo affects carotid intima media thickness (CIMT), diastolic function, peripheral vascular 
resistance, endothelial function and lipid profile. SHyper is associated with increased risk of atrial 
fibrillation (AF) (HR 1.68, 95%CI 1.16-2.43) and CHD events (HR 1.21, 95%CI 0.99-1.46). The TSH 
threshold for initiating treatment is unclear. In the absence of large randomized controlled trials, the best 
evidence suggests SHypo therapy should be started at TSH≥10 mIU/l, and SHyper therapy at TSH<0.1 
mIU/l. Recommendations on screening are discordant, but most guidelines advocate that thyroid function 
should be checked in those at risk for hypothyroidism, those over 60, and those with known CHD and HF. 
This review updates current evidence on the association between thyroid dysfunction and cardiovascular 
disease, as well as on screening and treatment of subclinical thyroid dysfunction. 
Keywords: subclinical hypothyroidism; subclinical hyperthyroidism; TSH; cardiovascular diseases; 
screening; treatment. 
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Clinical and Epidemiological Relevance of Subclinical Thyroid Dysfunction 
Subclinical thyroid dysfunction comprises subclinical hypothyroidism (SHypo) and subclinical 
hyperthyroidism (SHyper). SHypo is defined as Thyroid-Stimulating-Hormone (TSH) above the 
normal range, with normal free thyroxine (FT4) (1). SHypo can reach up to 10%, and is most 
prevalent among elderly women (2). Recent data show that SHypo is associated with coronary heart 
disease (CHD) (3-7), heart failure (HF) (8), and stroke (9). Endogenous subclinical hyperthyroidism 
(SHyper) is defined as low or undetectable TSH, with FT4 and free triiodothyronine (FT3) within the 
reference range. SHyper is associated with increased CHD events, CHD mortality, and incident AF 
(10). In the National Health and Nutrition Examination Survey III, 0.7% of participants had TSH<0.1 
mIU/l and 1.8%<0.4 mIU/l (11). The prevalence of SHyper depends on age, sex and iodine intake 
(12). Exogenous SHyper is caused by thyroid hormone replacement in up to 20% of treated patients. A 
retrospective cohort study on levothyroxine prescription among 52,298 participants showed that after 
5 years of treatment, 5.8% of participants had TSH< 0.1 mIU/l (13). 
Biochemical Definition of Subclinical Thyroid Dysfunction and Variations according to 
Population Characteristics 
Third generation TSH chemiluminometric assay is widely used and allows to detect changes of 
approximately 0.01 mIU/l. TSH within the hyperthyroid range can now reliably be distinguished from 
euthyroid, although there is still debate over the lower limit of the TSH reference range (14). For 
SHypo, controversy remains about the TSH range and upper limit (15-17). Most guidelines set an 
upper limit of 4.4 to 5.0 mIU/l, but the majority of euthyroid individuals fall between 0.4 and 2.5 
mIU/l, depending on their iodine intake (2, 18). Observational studies show that TSH tends to increase 
with age (19, 20), which seems to be a physiological process and a marker of frailty rather than a 
pathological development. There might be a danger of SHypo overdiagnosis, especially in the elderly, 
but age-based cut-off points have not yet been standardized (21). The underlying mechanisms leading 
to overt hypothyroidism, characterized by TSH above and FT4 below the reference range, are still not 
clear, though, one study described the average yearly progression rate as ranging from 2% to 6%, 
depending on the presence of antithyroid peroxidase antibodies (TPOAb) and on initial TSH (22). 
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General Pathophysiological Aspects 
Each individual probably has a specific, genetically determined set point for the hypothalamic-
pituitary-thyroid axis (23-25). A Danish twin study found heritability accounted for 64% of TSH 
variation (95%CI: 57-70%), 65% of FT4 variation (95%CI: 58-71%), and 64% of FT3 variation 
(95%CI: 57-70%) (25). FT4 plays the most important role in regulating TSH secretion (Figure 1). 
Minimal changes in FT4 have a strong effect on TSH secretion (26), but the earlier description of the 
regulating mechanism as a log-linear relationship between TSH and FT4 has been challenged. 
Mathematical models show the relationship is better represented by two overlapping sigmoid curves, 
where TSH is expected to be higher for men and the elderly (27). Symptoms of thyroid dysfunction 
are sometimes nonspecific: fatigue and depression are frequent, as are dyslipidaemia, weight gain, 
constipation. More extreme symptoms are pericardial effusion and myxoedema. Subjects with SHypo 
rarely report the full cluster of symptoms, but frequently report symptoms like tiredness (28), cramps, 
weakness and myalgia (29). Clinical manifestation of SHyper is less pronounced than it is for overt 
hyperthyroidism (characterized by low or undetectable TSH and FT3/FT4 above the reference range). 
For SHyper, symptoms may be absent or similar to overt hyperthyroidism (12): increased metabolic 
basal rate and thermogenesis (systemic symptoms) (12), sinus tachycardia, atrial fibrillation, 
congestive heart failure, and peripheral vasodilation with ankle oedema (cardiac symptoms) (30, 31). 
Thyroid Dysfunction and the Heart: Pathophysiological Mechanisms 
Peripheral deiodinases convert thyroxine to triiodothyronine, the active form of thyroid hormones. 
Within the cell, triiodothyronine is a transcriptional and extranuclear modulating factor that stimulates 
activity of cardiac myocytes and vascular smooth muscle cells. Triiodothyronine regulates the 
expression of structural and functional proteins, like calcium-activated ATPase and phospholamban, at 
DNA level (32). Triiodothyronine also regulates the intracellular calcium concentration, and 
determines systolic contractile function and diastolic relaxation. Triiodothyronine interacts directly 
with sodium, potassium, and calcium channels, modulating ionic exchange between intra- and 
extracellular compartments, and improving cardiac inotropy and chronotropy (32, 33) (Figure 2). 
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Overt hypothyroidism can cause cardiac anomalies,  including (i) rhythmic disorders like bradycardia 
and atrioventricular block (30); (ii) myocardial abnormalities like impaired systolic function, increased 
left ventricular (LV) diastolic filling, diastolic dysfunction with impaired cardiac relaxation, 
pulmonary hypertension, atrial stiffness, pericardial effusion; and, (iii) vascular disturbances like 
endothelial dysfunction and arterial hypertension (33) (Figure 3). LV stroke volume can be decreased 
by bradycardia, increased diastolic pressure, atrial stiffness and poor contractility, which can also 
aggravate HF (32, 34). LV ejection fraction is the most widely reported outcome in studies on heart 
failure and coronary heart disease for risk stratification and medical decision (35). Global heart 
function is the result of the interaction of myocardial contractility, preload (end-diastolic volume), 
heart rate and afterload. Because half of patients with HF events have preserved ejection fraction, 
guidelines recommend to use additional endpoints of diastolic function and LV pressing filling, such 
as transmitral inflow patterns (E-wave, A-wave and E/A), pulsed TVI-derived early diastolic velocity 
of the mitral annulus (E/e’ ratio) and left atrial volume (35). 
In SHypo anomalies are more common at higher TSH and among the elderly (36). It is specifically 
associated with diastolic dysfunction. Case-control studies found patients with SHypo have prolonged 
Isovolumic Relaxation Time (IRT), increased A wave, and diminished E/A ratio (36). In the 
Cardiovascular Health Study, the 3044 patients ≥65 years with TSH≥10 mIU/l had higher baseline 
peak E velocity (0.80 m/s) than those with normal TSH (0.72 m/s, P=0.002) (37). In addition, each 
0.1m/s increase in E wave velocity was associated with higher risk of HF events (HR 1.14, 95%CI 
1.08-1.18, P<0.001), especially with TSH≥10 mIU/l (HR 1.45, 95%CI 1.20-1.76) (37). 
Overt hyperthyroidism affects the cardiac pacemaker function and contractility (31, 38). SHyper, on 
the other hand, is associated with more premature atrial and ventricular beats, higher mean heart rate 
over 24 hours (12), and increased risk of atrial fibrillation (10). Cardiac changes in hyperthyroidism 
can be explained by the positive inotropic, chronotropic and lusitropic effects of triiodothyronine that 
might be associated with higher cardiovascular morbidity and mortality (12). The effects of thyroid 
hormones on the heart in hyperthyroidism mimic a hyper-adrenergic state although there is no 
evidence that thyroid hormones affect the responsiveness of the heart to catecholamines (Figure 3). 
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Some β-adrenergic elements in cardiomyocytes like the β1-adrenergic receptors and the adenylate 
cyclase are regulated by the thyroid hormones (31). 
Subclinical Thyroid Dysfunction and Surrogate Cardiovascular Markers  
Carotid Intima Media Thickness (CIMT) is a surrogate cardiovascular endpoint (39-41) associated 
with both SHyper and SHypo (12). CIMT may be an independent predictor for cardiovascular events, 
although its usefulness for classifying risk is still unclear (42). A meta-analysis found that each 0.10 
mm IMT increase corresponded to an increased RR for myocardial infarction of 1.15 (95%CI 1.12-
1.17) and for stroke of 1.18 (95%CI 1.16-1.21) (43). 
In a case-control study, CIMT was significantly higher among the 36 patients with SHypo (0.66 mm ± 
0.10) than the 32 controls (0.57 mm ± 0.08) (39). In a double-blind cross-over trial, 100 patients (mean 
age 53.8 years) with no prior thyroid dysfunction were randomized to 100 µg levothyroxine or placebo 
once a day for 12 weeks. After treatment, total lipoprotein decreased from 231.6 to 220 mg/dl; low-
density lipoprotein cholesterol decreased from 142.9 to 131.3 mg/dl. Brachial artery flow-mediated 
dilatation, a marker of endothelial function, improved after treatment, probably because of increased 
FT4 (28). Changes in coagulation and fibrinolytic cascade are related to SHypo, and might explain 
increased risk of stroke in those under 65 years observed in SHypo (9). 
SHyper, on the other hand, might be accompanied by changes in the coagulation cascade that increase 
the risk of thrombosis, although it is unclear if this risk is clinically relevant (12). 
The International Thyroid Studies Collaboration 
To better assess CVD risk in subclinical thyroid dysfunction, we setup the “Thyroid Studies 
Collaboration”, an international consortium that contributed individual participant data (IPD) from 18 
prospective cohorts, including 73,000 participants across 4 continents (4, 8-10, 44). Few cases of 
central hyperthyroidism were excluded from the analyses. For each cardiovascular outcome associated 
with SHypo and SHyper, we updated our systematic review of the literature (4, 8-10). IPD analyses 
allow analysis of specific subgroups with potentially different risk profiles, while study-level meta-
analyses may lead to aggregation biases with spurious subgroup data (9). IPD analyses best pool 
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evidence across studies; they allow (i) increase statistical power, (ii) adjust for similar confounding 
factors across studies, (iii) define similar TSH range, and (iv) standardize definitions of clinical 
outcomes (45). 
 
Current Evidence for Association between Subclinical Thyroid Dysfunction and Cardiovascular 
Diseases (CVD) 
The Thyroid Studies Collaboration examined the association between subclinical thyroid dysfunction 
and CHD events/mortality and HF, and clarified conflicting data from earlier prospective cohorts (46-
48). 
In a milestone IPD analysis of 11 prospective cohorts (4), 6.2% of the 55,287 participants had SHypo, 
but the vast majority (n=51,837) were euthyroid. 4,470 participants developed CHD events, among 
whom 430 (9.6 %) had SHypo. Hazard ratios (HR) for CHD mortality were: 1.09 (95%CI, 0.91-1.30) 
with TSH 4.5 to 6.9 mIU/L; 1.42 (95%CI, 1.03-1.95) for TSH 7.0-9.9 mIU/l; and 1.58 (95%CI, 1.10-
2.27; P=0.005 for trend) for TSH>10 mIU/l (Figure 4). SHypo did not increase total mortality. 
A similar IPD analysis on the association of SHypo and HF in 25,390 participants (8.1% with SHypo) 
found that HF risk increased both with higher and lower TSH (P for quadratic pattern<0.01) (Figure 
4); 2,069 participants had HF events, of whom 250 (12.1%) had SHypo and 57 (2.8%) SHyper (8). 
An IPD analysis with 52,674 participants from 10 cohorts (4.2% with SHyper) showed an association 
between SHyper and total mortality (HR 1.24, 95%CI, 1.06-1.46), CHD mortality (HR 1.29, 95%CI, 
1.02-1.62), CHD events (HR 1.21, 95%CI, 0.99-1.46), and AF (HR 1.68, 95%CI, 1.16-2.43). 3,653 
participants had CHD events, of whom 108 (2.9%) had SHyper. In subgroup analyses of CHD 
mortality and AF, TSH<0.10 mIU/l was associated with higher HR (2.54, 95%CI, 1.08-5.99) (10). 
Finally, an IPD analysis of 47,573 individuals from 17 cohorts (SHypo prevalence 0.4-16.3%, mean 
7.3%) reported increased risk of fatal stroke in SHypo for those 18-49 years old (HR 4.22; 95%CI, 
1.08-16.55) and 50-64 years old (HR 2.86; 95%CI, 1.31-6.26). A pattern of increased stroke risk for 
higher TSH levels was identified: In age- and sex-adjusted analyses the HR for fatal stroke was 1.18 
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(95%CI, 0.83-1.69) at TSH 4.5-6.9 mIU/l, 1.63 (95%CI, 1.09-2.43) at TSH 7.0-9.9 mIU/l and 1.69 
(95%CI, 0.88-3.27) at TSH 10.0-19.9 mIU/l (9). 
Impact of Thyroid Hormones Replacement on Cardiac Function and Cardiovascular Imaging 
Current data show several cardiac function parameters normalized in patients treated for SHypo. 
Levothyroxine in SHypo decreased the ratio between pre-ejection period and left ventricular ejection 
time decreased in 46 adults (49) and improved cardiac preload and contractility in 30 women (50). In 
10 patients with SHypo, Isovolumic Relaxation Time and the A wave dropped after treatment, and 
E/A ratio increased (1.3±0.3 to 1.7±0.4, P<0.001) (36) (eTable 1A, supplementary data). Studies 
were limited by small sample size, short duration, non-standardized definitions of SHypo and echo 
measurements. 
Impact of Thyroid Hormones Replacement on CIMT 
Some evidence (eTable 1B, supplementary data) shows CIMT regressed after thyroid function 
normalized. In a double-blind controlled trial, levothyroxine reduced CIMT from 0.76±0.14mm to 
0.67±0.13mm (P=0.03) (40). CIMT decreased from 0.67±0.11mm to 0.60±0.10mm (P=0.02) in 
SHypo treated with levothyroxine for a year (39). In a before-after trial including 34 patients with 
SHypo, CIMT decreased, after a year of levothyroxine replacement, from 0.64±0.02 mm to 0.55±0.02 
mm (P<0.001), total cholesterol from 5.99±0.25 mmol/l to 4.80±0.20 mmol/l (P<0.001); and low-
density lipoprotein cholesterol (LDL-C) from 3.65±0.23 mmol/l to 2.75±0.19 mmol/l (P=0.005) (41). 
Clinical issues for Screening and Treatment of Subclinical Thyroid Dysfunction and the TRUST 
Trial 
Indications for screening and thresholds for treating SHypo and SHyper are uncertain because 
randomized clinical trials (RCT) with relevant clinical outcomes are lacking (51-53) and information 
on long-term risks is limited (54). Current evidence is mostly based on observational studies, but also 
guidelines, expert committees and small randomized which have systematically been reviewed by the 
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United States Preventive Services Task Force (USPSTF) in 2015 (55, 56). Large randomized trials are 
needed to provide more evidence for screening and treatment of subclinical thyroid dysfunction. 
The TRUST Trial, a blinded multicentre RCT funded by the EU-FP7 (Proposal 278148-2, 
ClinicalTrials.gov, NCT01660126), has been set up to investigate the multi-modal impact of treatment 
on quality of life and symptoms, and cardiovascular markers. Follow-up will continue until the end of 
2016, shedding light on thresholds and benefits of levothyroxine in SHypo. 
 
Recommendation for Screening based on Current Evidence 
Current guidelines (57, 58) advocate measuring TSH for specific conditions (4, 8, 59). Patients with 
previous thyroid disorder, hypothalamic-pituitary disorder, and history of autoimmune disease could 
benefit from TSH monitoring because they are at increased risk of overt hypothyroidism (12). TSH 
testing could benefit those with abnormal values or changes in lipid profile (60), hyponatremia, 
unclear elevation of creatinine kinase, anaemia, and thyroid altering medication should since all these 
laboratory findings are associated with higher risk of thyroid dysfunction, especially hypothyroidism 
(61). According to the USPSTF, there is currently insufficient evidence for weighing the benefits and 
harms of early screening (55, 56). The American Academy of Family Physicians and the American 
College of Physicians (ACP) recommend thyroid function be checked regularly in older women (>50 
years for ACP). The American Thyroid Association (ATA) and the American Association of Clinical 
Endocrinologists (AACE) advocate assessing thyroid function in any patient at risk for 
hypothyroidism, and measuring TSH in those >60 (62). 
Recommendation for Treatment Based on Current Evidence 
Current recommended thresholds for starting thyroid hormone replacement are based on observational 
data and clinical trials with short follow-up. Their results suggest a TSH treatment threshold ≥10 
mIU/L (62), also recommended by the ATA and AACE. The decision to treat TSH <10 mIU/l should 
be taken individually, according to the risk profile of each patient (62). Patients with cardiovascular 
disorder or at high risk of developing overt hypothyroidism might benefit from earlier therapy (1, 62), 
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though opinions conflict (56). Some have argued for the use of liothyronine (synthetic 
triiodothyronine), either alone or in combination with levothyroxine, for better control of thyroid 
function, however the current evidence is too short-term and limited to recommend this form of 
treatment (63). Especially in older people, overtreatment is common and can cause severe adverse 
events like arrhythmia and HF exacerbation (64). According to the ATA and AACE, treatment if 
TSH<0.1 mIU/l might be reasonable in high risk patients, including those with cardiac arrhythmias, or 
postmenopausal women at risk of or with known osteoporosis. In other cases, careful clinical and 6-
monthly laboratory follow-up seems appropriate (51). 
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eTable 1A and eTable 1B, supplementary data 
Figures: 
Figure 1: Simplified illustration of thyroid hormones homeostasis. TRH: Thyrotropin-Releasing 
Hormone, TSH: Thyroid-Stimulating Hormone, T4: Thyroxine; T3: Triiodothyronine 
Figure 2: Effect of T3 on the cardiomyocytes. T3: Triiodothyronine 
Figure 3: Some mechanisms by which thyroid dysfunction affects the cardiovascular system 
Figure 4: HRs for Coronary Heart Disease Mortality (black) and Heart Failure Event (red) based on 
TSH Levels (adapted from (4, 8)). Age- and sex-adjusted HRs and their 95% confidence intervals 
(CIs), presented by squares (Reproduced with permission from (59)) 
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